_DSC0358-2d.jpg
Sensor in arm1.jpg
Hanske.jpg
TheTeam2.jpg
_DSC0358-2d.jpg

Glucose control


Glucose control results in reduced mortality, complication rate and hospital costs     

SCROLL DOWN

Glucose control


Glucose control results in reduced mortality, complication rate and hospital costs     

Glucose Control

mortality.jpg
 

REDUCED MORTALITY

High blood glucose increases the risk of dying, and safely normalizing it reduces mortality.

complications.jpg
 

REDUCED COMPLICATIONS

Sepsis and renal failure, dangerous ICU-complications, become less common when blood glucose is normalized.

cost.jpg
 

SAVED COSTS

Reducing length of stay and particularly reducing sepsis incidence has an impact on the hospital's ICU costs. 

Sensor in arm1.jpg

Product


GlucoSet enables normal blood glucose in ICU patients with its high accuracy, especially in the hypoglycemic range

SCROLL DOWN

Product


GlucoSet enables normal blood glucose in ICU patients with its high accuracy, especially in the hypoglycemic range

Product

normalise.jpg
 

ENABLING NORMAL BLOOD GLUCOSE

The large NICE-SUGAR-trial proved that normalizing blood glucose without new technologies were unsafe. 

accurate.jpg
 

VERY HIGH ACCURACY

A GlucoSet prototype tested in published porcine trials showed higher accuracy than any other intravascular glucose sensors over a wide blood glucose range. 

superior_at_low.jpg
 

SUPERIOR AT LOW GLUCOSE LEVELS

The published accuracy data are over a wide blood glucose range, but the sensor is even more accurate in the hypoglycemic range - where accuracy matters the most.  

An indwelling vascular sensor, particularly one as accurate as [the GlucoSet prototype], should be viewed as a significant advancement.
— Inzucchi & Kosiborod, editors of Anesthesiology in 2011, on published GlucoSet data

The GlucoSet continuous blood glucose monitoring is currently in development, currently in the preclinical stage. Read more about the technology here.

Hanske.jpg

Technology


A flexible technology platform that is scalable and based on strong IPR

SCROLL DOWN

Technology


A flexible technology platform that is scalable and based on strong IPR

Technology

superior.jpg
 

SUPERIOR PLATFORM

The GlucoSet technology platform is more accurate than other glucose sensing technologies because of the patented solution that allows measurement accuracy of gel length changes in the range of nanometers.

scalable.jpg
 

SCALABLE TECHNOLOGY

The technology is well-suited for scalable manufacturing processes, making small volume production possible at low cost as well as automated large scale production.

 

ip.jpg
 

STRONG IPR

GlucoSet holds several patents that cover both the technology platform and the manufacturing process, and patents new innovations in line with the company's IP strategy.

TheTeam2.jpg

About us


The team consists of dedicated specialists, experienced medtech entrepreneurs and international experts.

SCROLL DOWN

About us


The team consists of dedicated specialists, experienced medtech entrepreneurs and international experts.

About us

Executive team

DEDICATED SPECIALISTS

The GlucoSet core team has both expert researchers and the necessary understanding of the medical field. Through seasoned technical advisors, the team has access to years of know-how and knowledge. 

Board

ACCOMPLISHED ENTREPRENEURS

The board members contribute to the company with years of experience from medtech entrepreneurship and business development.

Advisory board

INTERNATIONAL EXPERTS

The advisory board consists of international experts within their fields, either as clinical experts or in medtech business development.


Need to get in touch with us? Use the contact form.